Despite significant advances in endocrinology, there are still large unmet needs for effective and safe treatments, especially for rare endocrine and metabolic diseases. We acknowledge that there is a need for more research and development activities to provide better care for these patients and are building and rapidly advancing a pipeline of innovative peptides.
Therapeutic peptides are particularly well suited as drugs for endocrine diseases, because many hormones are peptides or proteins.
Our portfolio currently includes:
- AZP-3601, a potential treatment for hypoparathyroidism
- AZP-3800, a small peptide series under evaluation to select a development candidate for the treatment of acromegaly
- AZP-3404, which is undergoing indication prioritization work
With our team’s established expertise in therapeutic peptides, we aim to further expand and rapidly advance our pipeline of promising innovative peptides through global approval.